Autoimmune adverse event following COVID-19 vaccination in Seoul, South Korea
Journal of Allergy and Clinical Immunology · 2024-06 · 153 (6) · 1711-1720
DOI: 10.1016/j.jaci.2024.01.025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2024-06. Verfasst von Hong Jin Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Inje University Sanggye Paik Hospital, College of Medicine, Inje University, Seoul, Korea. Hauptthemen laut MEDLINE: Autoimmune Diseases, COVID-19, COVID-19 Vaccines, Vitiligo. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: There is growing evidence that the coronavirus disease 2019 (COVID-19) vaccination can affect the regulation of the immune system, leading to the development of autoimmune diseases. However, the autoimmune adverse events (AEs) after COVID-19 vaccination remain largely unclear. OBJECTIVE: We sought to investigate the autoimmune AEs after COVID-19 vaccination from a population-based cohort in South Korea. METHODS: A total of 4,203,887 participants, representing 50% of the population residing in Seoul, were recruited from the National Health Insurance Service database and then divided into 2 groups on the basis of COVID-19 vaccination. The cumulative incidence, hazard ratios (HRs), and 95% CIs of autoimmune AEs were assessed following COVID-19 vaccination. RESULTS: The incidence of vitiligo has been observed to be significantly higher in the vaccination group compared with the no vaccination group. The cumulative incidence of vitiligo began to show a significant difference starting 2 weeks after vaccination, and it reached 2.2% in the vaccination group and 0.6% in the no vaccination group by 3 months after COVID-19 vaccination. Vitiligo (HR, 2.714; 95% CI, 1.777-4.146) was an increased risk among autoimmune AEs. Furthermore, the risk of vitiligo was the highest for heterologous vaccination (HR, 3.890; 95% CI, 2.303-6.573) compared with using cDNA vaccine (HR, 2.861; 95% CI, 1.838-4.453) or mRNA vaccine (HR, 2.475; 95% CI, 1.607-3.813). CONCLUSIONS: Vitiligo as an autoimmune AE was noted to be substantially higher in the COVID-19-vaccinated group compared with the controls. Therefore, the occurrence of vitiligo could be considered as one of the significant AEs post-COVID-19 vaccination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedic Surgery, Inje University Sanggye Paik Hospital, College of Medicine, Inje University, Seoul, Korea.
- Informatization Department, Ewha Womans University Seoul Hospital, Ewha Womans University, Seoul, Korea.
- Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, School of Medicine, Ewha Womans University, Seoul, Korea.
- Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, School of Medicine, Ewha Womans University, Seoul, Korea. Electronic address: cem@ewha.ac.kr.
Zitieren
APA
Kim, H. J., Kim, M. H., Park, S. J., Choi, M. G., & Chun, E. M. (2024). Autoimmune adverse event following COVID-19 vaccination in Seoul, South Korea. Journal of Allergy and Clinical Immunology, 153(6), 1711-1720. https://doi.org/10.1016/j.jaci.2024.01.025
Vancouver
Kim HJ, Kim MH, Park SJ, Choi MG, Chun EM. Autoimmune adverse event following COVID-19 vaccination in Seoul, South Korea. Journal of Allergy and Clinical Immunology. 2024;153(6):1711-1720. doi:10.1016/j.jaci.2024.01.025
BibTeX
@article{Kim2024,
author = {Kim, Hong Jin and Kim, Min-Ho and Park, Seong Jun and Choi, Myeong Geun and Chun, Eun Mi},
title = {Autoimmune adverse event following COVID-19 vaccination in Seoul, South Korea},
journal = {Journal of Allergy and Clinical Immunology},
year = {2024},
volume = {153},
number = {6},
pages = {1711--1720},
doi = {10.1016/j.jaci.2024.01.025}
}
EUVIMED